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Abstract 
The immuno-modulatory properties of airway smooth muscle have become of 
increasing importance in our understanding of the mechanisms underlying chronic 
inflammation and structural remodeling of the airway wall in asthma and chronic 
obstructive pulmonary disease (COPD).  ASM cells respond to many cytokines, growth 
factors and lipid mediators to produce a wide array of immuno-modulatory molecules 
which may in turn orchestrate and perpetuate the disease process in asthma and COPD.  
Despite numerous studies of the cellular effects of cytokines on cultured ASM, few have 
identified intracellular signaling pathways by which cytokines modulate or induce these 
cellular responses.  In this review we provide an overview of the transcriptional 
mechanisms as well as intracellular signaling pathways regulating cytokine functions in 
ASM cells.  The recent discovery of toll-like receptors in ASM cells represents a 
significant development in our understanding of the immuno-modulatory capabilities of 
ASM cells.  Thus, we also review emerging evidence of the inflammatory response to 
toll-like receptor activation in ASM cells.   
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Introduction 
Cytokines and chemokines play a central role in regulating inflammatory and 
immune responses in chronic lung diseases such as asthma and COPD. Indeed, in vivo 
studies using selective inhibitors as well as neutralizing antibodies against various 
cytokines and chemokines demonstrate their importance in antigen-induced airway 
inflammation (leukocyte infiltration) and hyper-responsiveness in animal models of 
asthma [1-3]. Studies in knock-out or transgenic mice also illustrate the importance of 
cytokines in the abnormal airway changes induced by allergen challenge in sensitized 
animals [4].  A potential site for the deleterious action of many cytokines in airways 
disease is the airway smooth muscle a primary effector tissue historically thought to only 
regulate bronchomotor tone. In human cultured ASM cells that retain physiological 
responsiveness, cytokines alter pro-inflammatory gene expression that in turn may play 
an important role in the pathogenesis of chronic inflammatory airways disease [5].  
Despite numerous studies of the cellular effects of cytokines on cultured ASM, few have 
identified downstream signaling cascades by which cytokines modulate or induce these 
cellular responses.  In this review we discuss the role of three major intracellular 
signaling pathways: Mitogen-Activated Protein Kinase (MAPK), Nuclear Factor-kappa B 
(NF-κB), and Janus kinases and Signal Transducers and Activators of Transcription 
(STATs) in regulating cytokine functions, with a particular focus on inflammatory gene 
expression, in regulating ASM functions.  
The capacity for ASM cells to respond to numerous cytokines has revealed the 
extensive immune-regulatory potential of these cells.  In response to cytokines such as 
IL-1β, TNF-α and IFN-γ, ASM cells can be induced to express a host of cell-adhesion 
and co-stimulatory molecules that allow interactions between the ASM and inflammatory 
cells that infiltrate the airways.  Moreover, ligation of ASM cell-surface molecules such 
as CD40 and OX40L by their respective counter-ligands leads to activation of ASM 
inflammatory responses.  Further advances in understanding the immune-regulatory 
potential of ASM have come with the discovery that cytokines also up-regulate the 
expression of multiple toll-like receptors (TLRs) in ASM cells.  These latter receptors are 
pattern-recognition receptors that mediate innate and adaptive immune and inflammatory 
responses to microbial infection, tissue injury or inflammation.  Emerging evidence now 
suggests a role for TLRs in the development, perpetuation and exacerbation of chronic 
inflammatory airway disease [6].   Thus, we also discuss the potential role of TLRs in the 
amplification of ASM inflammatory responses.  
 1. MAPKs  
The MAPK signal transduction pathway consists of MAPK, MAPK kinase 
(MEK, MAPKK, or MKK), and MAPK kinase kinase (MEKK, MAPKKK, or MKKK). 
The MAPK cascade activation occurs by sequential phosphorylation of Thr-X-Tyr 
motifs. In mammalian cells, there are five distinct subfamilies including extracellular 
signal-regulated kinase (ERK), p38 MAPK (p38), c-Jun N-terminal kinase (JNK), 
ERK3/4 and ERK5. Among the five distinctive MAPK pathways, ERK, p38 MAPK and 
JNK have been extensively studied in ASM cells [7] (Figure 1).  
 
1.2 MAPK signaling in ASM inflammatory gene expression 
(a) p42/44 ERK 
ERK signaling induces downstream activation of different intracellular 
transcription factors such as Elk-1, c-fos, c-myc, Sap-1, and Tal, and consequently 
modulates DNA synthesis and cell proliferation [8]. In ASM, activation of ERK signaling 
is elicited by various stimuli including platelet derived growth factor (PDGF), epidermal 
growth factor (EGF), basic fibroblast growth factor (bFGF), endothelin-1 (ET-1), 
thrombin, oncostatin M, leukemia inhibitory factor (LIF), insulin-like growth factor I, 
and 5-hydroxytryptamine [9-14].  Cytokines are also important activators of ERK 
signaling.  Phosphorylation of ERK1/2 by IL-1β leads to production of numerous 
inflammatory mediators including prostaglandin-E2 (PGE2), eotaxin, RANTES, and 
GM-CSF [15]. ERK is also involved in mediating ASM eotaxin and IL-8 release in 
response to Th2 cytokines (IL-4, IL-9, IL-13) and the Th17 cytokine IL-17 [16-18].  The 
interleukin-17B receptor (IL-17BR) is also up-regulated in ASM cells in an ERK-
dependent manner [19].   
 
(b) p38  
p38 signaling is activated in response to physical and chemical challenges 
including oxidative stress, UV irradiation, hypoxia, ischemia as well as various cytokines 
[20, 21].  The down-stream effectors of this cascade are transcription factors such as Elk-
1, Sap-1, ATF-2, CREB, CHOP, and Max. p38 mediates bFGF-induced ASM 
proliferation [22] and ASM inflammatory gene expression in response to multiple 
stimuli.  Indeed, p38 MAPK mediates IL-17A induced IL-6, IL-8 and eotaxin secretion 
[23-26] as well as bradykinin induced IL-6 secretion [27].  Although there are no 
published reports of the MAPKs regulating IL-5 secretion, p38 regulates expression of 
the IL-5 receptor (IL-5R) in response to IL-1β, TNFα and IFN-γ [28].  p38 MAPK 
appears to have both positive and negative regulatory effects on cytokine-induced 
inflammatory responses in ASM; it acts to augment TNF-α-induced IL-6 and RANTES 
release and IL-1β-induced eotaxin release, but inhibits TNF-α induced ICAM-1 
expression and IL-1β induced GM-CSF release [15, 29].  This suggests a gene specific 
role of p38 MAPK in regulating specific transcriptional outcomes.  
We recently made the novel finding that, under basal conditions, p38 negatively 
regulates IFN-β promoter activity (Damera et al., unpublished data).  In line with this, 
treatment of ASM cells with the p38 inhibitor SB203580 showed a specific reduction in 
tonic p38 activity and enhanced IFN-β transcription and protein secretion. Functional 
studies using an IFN-β neutralizing antibody reversed the inhibitory effect of SB203580 
on TNF-α-induced IL-8 secretion, indicating an important role of autocrine IFN-β in 
regulating p38-dependent inflammatory responses.  
 
(c) c-Jun NH2-terminal kinases (JNK)  
JNK signaling is activated by environmental stress, pro-inflammatory cytokines 
and genotoxic agents. Following activation of JNK, three Jun transcription factors (JunB, 
c-Jun and JunD), which are all members of the AP-1 family, are activated [30].  These 
transcription factors modulate gene expression responsible for many biological responses, 
including migration, proliferation, differentiation and cell death [31].  In murine studies, 
administration of the JNK inhibitor SP600125 after allergen challenge prevents T cell-
mediated inflammation and ASM cell proliferation, indicating a role for JNK signaling in 
allergic airway inflammation and remodeling [32].  Studies using the JNK inhibitor 
SP600125 implicated JNK in the regulation of IL-1β- and TNF-α-induced RANTES, 
GM-CSF, and IL-8 secretion in ASM cells [33].  IFN-γ and TNF-α induced fractalkine 
expression also occurs through JNK dependent mechanisms [34]. 
 
1.2 Implications of MAPK cross-talk in ASM cells 
  While unique stimuli initiate the majority of cellular responses by specific 
signaling cascades, it is not uncommon to derive such responses by multiple and parallel 
signaling cascades. Exogenous addition of TGF-β1 to ASM cultures increases [3H]-
thymidine incorporation and ASM cell proliferation via ERK, p38 and JNK-dependent 
pathways [35].  Similarly, TNF-α-mediated induction of CD38, a potent modulator of 
calcium homeostasis and ASM tone, involves all MAPK cascade components [36].  The 
induction of matrix metalloproteinase-9 (MMP-9) expression by cytokines also involves 
active participation of several MAPK pathways [37, 38].  Interestingly, in some 
instances, the induction of one MAPK pathway may antagonize another. Indeed, LPS-
induced activation of p38 MAPK down-regulates changes in ASM responsiveness and 
IL-6 secretion associated with ERK1/2 activation [39]. 
 
2. NF-κB  
Nuclear factor-kappa B (NF-κB) is a ubiquitously expressed transcription factor 
that mediates the expression of many inflammatory mediators, including cytokines, 
adhesion molecules, chemokines, and growth factors [40].  NF-κB-dependent pro-
inflammatory genes are believed to play a central role in a variety of inflammatory 
diseases including chronic inflammatory airway diseases such as asthma. Increased 
markers of NF-κB pathway activity have been demonstrated in the airways of, or samples 
from, asthma patients [41-45] as well as in rodent models of asthma [46-49].  For this 
reason, the NF-κB signalling pathway is an attractive target for novel asthma therapies.  
Indeed, studies have shown that targeting NF-κB, using various molecular 
methodologies, inhibits aspects of the allergic response in rodent models of asthma [50-
56].  
 
2.1 NF-κB signaling cascade 
NF-κB is activated in response to a number of stimuli, including physical and 
chemical stress, lipopolysaccharide (LPS), double-stranded RNA, T- and B-cell mitogens 
and pro-inflammatory cytokines [57]. NF-κB induced gene expression is controlled by a 
complex series of enzymatic signalling events at multiple levels. An overview of the NF-
κB activation cascade is depicted in Figure 2. 
NF-κB is made up of a hetero- or homodimer of members of the DNA-binding 
Rel family of proteins which contains five known mammalian members: p50 (NF-κB1, 
precursor of which is p105), p65 (Rel A, NF-κB3), p52 (NF-κB2, precursor of which is 
p100), c-Rel and Rel B.  The p65 and p50 subunits are ubiquitously expressed, whereas 
p52, c-Rel and Rel B are restricted to specific differentiated cell types [58]. In resting 
cells, the majority of NF-κB is bound to I-κB inhibitory protein, which holds the complex 
in the cytoplasm. Upon cellular stimulation, the I-κB protein is phosphorylated, 
ubiquinated, and degraded by the proteosomal pathway.  With the I-κB removed, NF-κB 
translocates to the nucleus and mediates gene transcription [59] 
I-κB phosphorylation and activation of Rel proteins can occur via the classical 
(canonical) or non-classical (non-canonical) pathway.  In the classical pathway, a critical 
phosphorylation of the I-κB protein is performed by the I-κB kinase (IKK) complex, 
which consists of at least three subunits, including two catalytic subunits IKK-α and -β, 
also known as IKK-1 and -2, and one regulatory subunit IKK-γ (also known as NEMO) 
[57]. Of the two catalytic subunits, IKK-β is 20 fold more active than IKK-α in the 
phosphorylation of I-κB [60].  It is also thought that IKK-β, not IKK-α, is critical for NF-
κB activation [61-64] and hence attempts to target this pathway for therapeutic 
intervention have focused on inhibitors of this subunit [65, 66]. Stimuli of the classical 
pathway include the TLR/IL-1R family members, ligation of the T-cell receptor (TCR), 
and TNFR signalling [59](Figure 2). IKK-2 has been shown to be critical in NF-κB 
activation in ASM cells [67, 68].   
In addition to the classical pathway, an alternative (non-canonical) pathway has 
been described mainly in B cells. This latter pathway can be activated by different stimuli 
such as lymphotoxin β, CD40 ligand, and receptor activator of NF-κB ligand [69, 70] 
The alternative NF-κB pathway is characterised by the inducible phosphorylation and 
processing of p100 to p52, and subsequent nuclear translocation of the heterodimer 
p52:Rel B is independent of IKKγ and IKKβ and only requires the IKKα subunit [71]. 
This pathway is believed to play key roles in adaptive immunity [72]. 
The NF-κB pathway can be further controlled by post translational modifications, 
including the modulation of Rel protein interactions with other components of the 
transcriptional machinery. Altered activation of NF-κB can occur via its phosphorylation 
status, for example the phosphorylation of p65 enhances transcription, yet 
phosphorylation of p105 can reduce its processing into p50 and hence reduce activation 
[73].  Acetylation of the Rel proteins also play a key role [74, 75]. Additionally, covalent 
modifications of the chromatin environment which regulates the access of transcription 
factors to gene promoters alter NF-κB-dependent transcription. This control is achieved 
by recruitment of protein complexes that alter chromatin structure via enzymatic 
modifications of histone tails and/or nucleosome remodelling. NF-κB activation requires 
several cofactor histone acetyltransferases, including CBP, p300, p/CAF, and SRC-1, of 
which p/CAF appeared to be relatively more important [74, 76]. 
 
2.2 NF-κB signaling in ASM inflammatory gene expression 
A multitude of studies in ASM cells implicate a role for NF-κB in the regulation 
of inflammatory chemokines, cytokines, and adhesion molecules. Indeed, NF-κB is 
involved in IL-17-induced IL-8 release [23, 77]; IL-1β and TNF-α-induced GRO-α 
release [78]; neutrophil-derived elastase-induced TGF-β expression [79]; in the 
expression of cell adhesion molecules such as ICAM-1 and VCAM-1 induced by TNF-α, 
IL-1β and LPS [80-82].  As stated above, IKK-2 plays a crucial role in the classical NF-
κB pathway and for this reason there has been considerable interest in studying and 
developing ways to manipulate this kinase in order to identify new therapeutics for the 
treatment of asthma. Data from ASM cells demonstrate that  inhibition of IKK2 using the 
small molecule inhibitors TPCA-1, PS-1145 and ML120B, or molecular intervention 
using adenoviral approaches to knock down IKK2, demonstrate a role for this kinase in 
the expression of ICAM-1, cyclooxygenase-2, IL-6, IL-8, GM-CSF, RANTES, monocyte 
chemotactic protein-1 (MCP-1), GRO-α, neutrophil-activating protein-2 (NAP-2), and 
epithelial neutrophil activating peptide 78 (ENA-78), some of which are upregulated and 
play a role in asthma pathogenesis [67, 68].  Similarly, in rodent models of asthma, 
modulation of IKK-2 using parallel molecular techniques, have shown positive disease 
modifying data [83-86]. These data suggest that inhibition of IKK2 and hence the NF-κB 
pathway may have therapeutic implications for asthma treatment. 
Of interest, TNF-α but not IL-1β activation of NF-κB signaling involves 
recruitment of the downstream transducer protein TRAF2 by TNF-α receptor 1 (TNFR1) 
via the receptor-associated death domain protein, TRADD [87, 88].  Similar findings 
were also reported in ASM cells from guinea pigs where TNFR1 activation with 
agonistic antibodies also induced NF-κB activation [89]. 
Recent work investigating pro-inflammatory stimuli on NF-κB activity with 
regard to phosphorylation and chromatin remodeling in ASM cells has emerged.  TNF-α 
has been reported to phosphorylate both IKK-β [90] and the p65 subunit at Ser276 and 
Ser536 in ASM cells [91]. In the latter study, the authors also demonstrated that TNF-α 
recruits the histone acetyl-transferase p/CAF to the CCL-11 (eotaxin) promoter to 
increase NF-κB mediated transactivation of this gene [91]. p300/CBP acetylation is also 
required for NF-κB mediated TNF-α-induced VCAM-1 and ICAM-1 induction in ASM 
cells [80, 92, 93].  
 
3. JAK/STATs  
The classical components of the IFN signaling cascade include the Janus tyrosine 
kinases and signal transducers and activators of transcription (STATs) factors. Activation 
of each IFN receptor complex stimulates different receptor-associated tyrosine kinases, 
namely, JAK1 and Tyk2 by IFN-α/β (type I), or JAK1 and JAK2 by IFN-γ (type II) [94].  
JAKs-mediated phosphorylation of STAT proteins results in STAT assembly in dimeric 
or oligomeric forms, which translocate to the nucleus, where they can regulate gene 
expression via DNA binding motifs called either γ-activated sequence (GAS) elements 
(recognized by STAT1 homodimers) or IFN-stimulated response element (ISRE, 
recognized by STAT1-STAT2 heterodimers) [95, 96].  Up-regulation of STAT1 and 
STAT1-dependent genes such as ICAM-1 and IFN regulatory Factor-1 (IRF-1) are 
observed in asthmatic airways suggesting the potential contribution of IFN-associated 
JAK/STATs in the regulation of immuno-modulatory genes associated with asthma [97]. 
 
3.1 Modulation of ASM synthetic functions by IFNs. 
IFNs regulate many cellular responses in human ASM cells: IFN-γ induces the 
expression of ICAM-1 and VCAM-1 [98], the CysLT1 receptor [99] and the secretion of 
nerve growth factor in ASM cells [100].  IFN-γ also synergizes with TNF-α to augment 
expression of CD38 [101] and several chemokines including RANTES, IP-10 and 
fractalkine [34, 102, 103].  Most studies that used a combination of IFN-γ and TNF-α 
showed that the synergistic action involves several molecular mechanisms. In some 
instances, their co-operativity may be explained by the IFN-γ-induced up-regulation of 
TNF-α receptors [104] or vice-versa [105] (Figure 3). Furthermore, both cytokines may 
collaborate at the gene level by increasing promoter activation through a synergistic 
interaction between transcription factors activated by IFN-γ (STATs, IRF-1) and TNF-α 
(NF-κB) [106, 107] (Figure 3). These amplifying properties of IFN-γ may explain, at 
least in part, why viral infection, which increases production of IFNs, is an important 
trigger for asthma and chronic obstructive pulmonary disease exacerbation [108].  
Another mechanism of co-operation could be secondary induction of IFN-β, which has 
been shown to mediate TNF-α induced RANTES and CD38 expression [101, 109] 
(Figure 3) (see below).  
In some instances, however, IFNs may antagonize TNF-α inflammatory 
responses by inhibiting the NF-κB pathway.  Indeed, Keslacy and colleagues recently 
reported that IFN-γ potently inhibits TNF-α-induced NF-κB-dependent genes including 
IL-6, IL-8 and eotaxin in ASM cells [90]. Multiple mechanisms underlying IFNs 
inhibitory effect on NF-κB pathways have been proposed including inhibition of NF-κB 
DNA binding, prevention of IκB degradation, or regulation of TNF-α receptor 1 via 
STAT interaction [110].  Specifically, in ASM cells, IFN-γ inhibits the transcriptional 
activity of NF-κB by reducing the acetylation level of p65 [90].  
3.2 Autocrine IFN-β regulates pro-asthmatic gene expression in ASM cells.  
In ASM cells, TNF-α is able to activate JAK1 and Tyk2, and STAT1- and 
STAT2-dependent gene expression via the autocrine action of IFN-β [109].  Indeed, 
autocrine IFN-β regulates i) TNF-α-induced inflammatory gene expression, by 
suppressing IL-6 and promoting RANTES secretion and ii) TNF-α-associated airway 
hyper-responsiveness, by potentiating the ability for TNF-α to enhance GPCR-dependent 
contractile responses [111, 112].   
The putative implication of IFN-β in lung diseases is supported by the heightened 
expression of IFN-β in the airways in mouse models of allergic asthma [111].  We 
therefore propose that the functional cross talk between type I and II IFNs and TNF-α in 
lung structural cells, particularly the ASM, is a novel axis in the pathogenesis of lung 
diseases, although a similar phenomenon could also occur in other cell types (such as 
hemopoieitic cells). A recent study by Ivashkiv and colleagues recently confirmed the 
inflammatory potential of IFN-β/TNF-α interaction in macrophages [113].  This elegant 
study showed that IFN-β-mediated autocrine loops were essential for maintaining TNF-
α-induced inflammatory genes that prime macrophages for augmented responses to 
additional stimulation by cytokines and toll-like receptors agonists.  In previous studies 
performed in 3T3-L1 adipocytes, TNF-α was shown to induce phosphorylation of 
STAT1 by directly interacting with both JAK1 and JAK2 [114], whereas in Hela cells, 
STAT1 was shown to physically interact with TNFR1 and the adaptor proteins TNF 
receptor–associated death domain (TRADD), but not TRAF-2 [115].  TNF-α also 
induces STAT1 phosphorylation at serine 727 in macrophages.  
In Summary, ASM-derived IFN-β is a novel signaling component of TNF-α 
inducible genes involved in airway inflammation (Figure 3) and regulation of airway 
hyper-responsiveness [111].   
3.3 IFNs interference with ASM steroid responsiveness 
Most anti-inflammatory effects of steroids are mediated via the glucocorticoid 
receptor alpha isoform (GRα), which suppresses expression of inflammatory genes 
through mechanisms known as transactivation or transrepression [116].  As a result of 
alternative splicing mechanisms, another glucocorticoid receptor isoform, namely GRβ, 
has been described [117].  We and others recently showed that treatment of ASM cells 
with the specific combination of IFNs with TNF-α impairs the ability of steroids to 
inhibit the expression of various pro-inflammatory genes such as CD38, RANTES and 
ICAM-1 by a mechanism involving the up-regulation of GRβ isoform [118].  
Interestingly, steroids augment IFN-γ/TNF-α induced fractalkine and TLR2 expression in 
ASM [34, 119]: whether this involves similar mechanisms involved in the attenuation of 
corticosteroid activity by IFN-γ/TNF-α remains to be established. Although the 
pathological role of the GRβ isoform is not well understood, previous reports 
demonstrate a strong correlation between steroid resistance in individuals with asthma 
and the expression levels of GRβ [120].  More importantly, increased GRβ in the airways 
has been detected in patients who died of asthma [121].  Indeed, by its ability to act as a 
dominant-negative inhibitor of steroid action in other cell types [122], GRβ has been 
associated with steroid resistance in different inflammatory diseases [123]. GRβ over-
expression in ASM cells also prevents the capacity for steroids to induce transactivation 
activity and inhibit cytokine-induced pro-inflammatory gene expression [118]. 
Interestingly, short-term treatment of ASM cells with IFNs and TNF-α inhibits, in 
a GRβ-independent manner, the capacity for steroids to induce transactivation partially 
through the cellular accumulation of IRF-1 [124].  IRF-1 is an early response gene 
involved in diverse transcriptional regulatory processes [125].  Interestingly, a strong 
association was found between IRF-1 polymorphism and childhood atopic asthma [126].  
Early steroid dysfunction seen after short incubation with IFNs and TNFα could be 
reproduced by enhancing IRF-1 cellular levels using constitutively active IRF-1 which 
dose-dependently inhibited glucocorticoid response element (GRE)-dependent gene 
transcription [124].  Consistently, reducing IRF-1 cellular levels using siRNA approach 
in TNF/IFN-treated ASM cells significantly restored steroid transactivation activities. 
These findings demonstrate for the first time that IRF-1 is a novel alternative GRβ-
independent mechanism mediating steroid dysfunction induced by pro-inflammatory 
cytokines. The fact that different studies showed that the expression of IRF-1 was largely 
increased after viral infections [127] combined with the suppressive effect of IRF-1 on 
steroid signaling in ASM cells [124], may explain the reduced steroid responsiveness 
seen in asthmatic patients experiencing viral infections [128]. 
 
4. TLRs in chronic inflammatory airways disease 
TLRs may be considered as a ‘sensing’ system that protects the host from 
infectious and non-infectious tissue injury and inflammation.  TLRs also serve a 
homeostatic role to maintain tissue integrity and regeneration.  TLRs ‘sense’ diverse 
molecules including microbial products and endogenous ligands generated in response to 
cell stress or injury.  Currently, there are 10 known human TLRs named TLR1 through 
TLR10.  TLR2 and TLR4, which primarily mediate recognition of bacterial cell wall 
components (eg LPS – the major ligand for TLR4) and endogenous ‘danger signals’ (eg 
heat shock proteins, extracellular matrix fragments) are the best studied of this receptor 
family.  TLR3, TLR7 and TLR8 mediate recognition of viral RNA whilst TLR9 mediates 
recognition of bacterial DNA containing CpG motifs.  Activation of TLRs triggers the 
activation of immune and inflammatory responses through NF-κB, IRF3/7 and MAP 
kinase dependent signaling pathways [6]. 
Epidemiological studies suggest that genetic polymorphisms in TLR genes, 
together with early-life exposure to environmental TLR stimulants (e.g. LPS in house 
dust, microbial exposure associated with certain farming activities, respiratory viral 
infections) are likely to be important, but also very complex, determinants of asthma 
incidence and severity.  On the converse, emerging evidence shows that allergic airway 
inflammation impairs innate host-defense mechanisms, including TLR function, which 
results in impaired bacterial clearance [129, 130].  This may offer some explanation for 
increased bacterial colonization in asthmatic lungs and also provides some basis for 
infective exacerbations of asthma.  Emerging evidence also indicates a role for TLR4 in 
the airway inflammatory response to cigarette smoke exposure, the primary causative 
factor of COPD [131-133].  
The demonstration of functional TLR expression in human ASM cells over the 
past few years adds to the growing body of evidence of the immuno-modulatory 
capabilities of ASM cells.  This has wide-ranging implications for the disease process in 
asthma and COPD, as activation of TLRs in ASM may exacerbate airway inflammatory 
responses by inducing expression of cell adhesion molecules and release of cytokines 
and chemokines, and may also amplify ASM-inflammatory cell interactions. 
 
4.1 TLR expression in ASM cells 
Human ASM cells in culture express TLR1 through TLR10 mRNA under basal 
conditions.  TLR2, TLR3 and TLR6 are the most highly expressed, whilst TLR4 is the 
least expressed [119].  Interestingly, in one study, constitutive expression of TLR7 or 
TLR8 was not demonstrated [134].  Whether this was due to cell donor differences, type 
of ASM cells used (eg tracheal vs bronchial; distal vs proximal) or methodological issues 
remains to be resolved. In addition to evidence of TLR gene expression, cell surface and 
intracellular protein expression for both TLR2 and TLR3 has also been demonstrated 
[119, 135].  TLR2, TLR3 and TLR4 expression in ASM cells is up-regulated in response 
to inflammatory cytokines including IL-1β, TNF-α and IFN-γ, and microbial products 
including LPS and dsRNA.  Combined stimulation with IFN-γ and TNF-α has 
synergistic and additive effects on TLR2 and TLR4 mRNA expression, respectively 
[119, 135].   
 
4.2 TLR activation and ASM inflammatory gene expression 
Evidence of TLR expression in ASM has fuelled recent interest in ASM cell 
inflammatory responses to TLR ligands.  Stimulation of ASM cells with synthetic TLR2 
ligands, LPS or poly IC induces the production of various cytokines and chemokines [39, 
119, 134-136]; Pam3CSK4 (a synthetic bacterial lipopeptide) and FSL-1 (S-(2,3-
bispalmitoyloxypropyl)-Cys-Gly-Asp-Pro-Lys-His-Pro-Ser-Phe), which activate 
TLR2/TLR1 and TLR2/TLR6 heterodimers, respectively, induce IL-8 release; LPS 
induces expression of IL-6, IL-8 and eotaxin; and polyriboinosinc-polyribocytidylic acid 
(poly IC) induces expression of IL-6, IL-8, eotaxin, RANTES and IP-10.  Stimulation of 
ASM cells with poly IC together with IL-1β or TNF-α has synergistic effects on IL-6, 
IL-8, IP-10 and RANTES release.  Interestingly, poly IC induced eotaxin expression is 
inhibited in the presence of IL-1β or TNF-α, but is augmented by the Th2 cytokine IL-4.  
The specific activation of TLR2 in mediating IL-8 release has not been confirmed 
in ASM cells, although anti-TLR2 or transfection with a dominant negative mutant form 
of TLR2 inhibits ERK1/2 signaling in response to the microbial derived TLR2 ligand 
lipoteichoic acid (LTA), thus providing functional evidence of TLR2 activation in ASM 
cells [137].  Although ASM cells express TLR3 on the cell surface and in intracellular 
endosomes, specific activation of endosomal rather than surface TLR3 was shown to be 
responsible for poly IC mediated eotaxin release [135].  The specific activation of TLR4 
in mediating LPS-induced cytokine and chemokine release in ASM cells remains to be 
established.  
 In addition to inducing ASM cell cytokine and chemokine release, activation of 
TLRs in ASM cells may also amplify airway inflammatory responses by facilitating 
ASM-inflammatory cell interactions.  This is demonstrated by studies showing that 
addition of TLR2, TLR4, TLR7 or TLR8 ligands to ASM cells in co-culture with 
peripheral blood mononuclear cells (PBMCs) leads to greater release of IL-6, IL-8 and 
CCL2 compared to TLR-activation of either cell type alone [134, 138].  IL-1β produced 
by LPS-activated monocytes was shown to be responsible, to some extent, for 
amplification of ASM-PBMC inflammatory responses [138].  Poly IC and LPS may also 
promote ASM-inflammatory cell interactions via inducing the expression of cell adhesion 
molecules such as ICAM-1 and VCAM-1, respectively [134].  Indeed, LPS has been 
shown to mediate VCAM-1-induced neutrophil adhesion in ASM cells [81]. 
 In vitro infection of human ASM cells with respiratory viruses such as rhinovirus 
or respiratory syncytial virus leads to production of several cytokines and chemokines 
including IL-1β, IL-6, IL-8 and IL-11 [139-141].  The role of TLRs in mediating these 
responses has not as yet been addressed, although it is likely that viral-sensing TLRs as 
well as other intracellular viral recognition proteins such as protein kinase R, and cell-
surface molecules such as ICAM-1 (which is a receptor for rhinovirus) are involved.  
Whether infection of ASM cells with respiratory viruses, or indeed other microbial 
pathogens that colonize the lungs in asthma and COPD, occurs in vivo is an important 
area of further investigation; especially given the potential impact of microbial-TLR 
interactions on ASM inflammatory responses.  
Activation of TLRs in ASM occurs not only in response to microbial-derived 
products but may also occur in response to endogenous molecules present within the 
inflammatory milieu.  Recently, it was shown that neutrophil-derived elastase (NE) 
activates ASM cells to synthesize TGF-β via a mechanism involving TLR4 and its 
associated down-stream signaling cascade.  However, stimulation of TGF-β synthesis by 
NE was only partially inhibited by a TLR4-blocking antibody indicating that other 
mechanisms or perhaps TLRs may be involved.  Interestingly, TLR4 protein expression 
on ASM was reduced following treatment with NE, indicating that NE-dependent TLR4 
responses may require internalization of the receptor [79].  
 Although our understanding of the role of TLRs in the pathogenesis of asthma 
and COPD is only just evolving, evidence of their pro-inflammatory functions in ASM 
further extends the role of ASM as a critical mediator of the airway inflammatory 
response, potentially having the capacity to respond to environmental as well as 
endogenous molecules involved in the perpetuation and exacerbation of airway 
inflammatory disease.  Studies of the expression and function of TLRs in ASM cells in 
vivo is an important area of future research. 
 
Conclusions  
Cytokines play a principal role in modulating inflammatory as well as immune 
responses in chronic inflammatory diseases such as asthma and COPD.  Pro-
inflammatory and immuno-modulatory cytokines activate multiple signaling cascades in 
ASM cells that lead to amplification of ASM inflammatory responses.  Research over the 
past decade has taken us forward in our understanding of MAPK, NF-κB and JAK/STAT 
signaling mechanisms involved in regulating ASM inflammatory gene expression and 
studies in animal models show that specific targeting of these pathways offer therapeutic 
potential for the treatment of chronic inflammatory airways disease [32, 68, 142-144].  
Whilst there is some advantage in targeting these signaling pathways in isolation, further 
understanding of the cross-talk mechanisms and pathway interactions that exacerbate 
inflammatory responses or impair steroid responsiveness in ASM cells may provide 
novel targets or approaches for the future therapy of chronic inflammatory airways 
disease.   
TLR ligands represent potentially exciting new therapeutic approaches for the 
treatment of asthma.  Indeed, several studies published in the last five years demonstrate 
protective effects of TLR2, TLR3, TLR4, TLR7/8 and TLR9 ligands against allergic 
airway inflammation, airway hyperreactivity and airway remodeling in animal models of 
asthma [145-152].  The mechanisms that underlie protection against asthma in these 
models are slowly being unraveled and studies so far have focused on delineating 
immuno-modulatory pathways.  However, evidence that the synthetic TLR7/8 ligand R-
848 imparts some of its protection against airway remodeling by inhibiting ASM 
proliferation [152] indicates that the ASM is a potential target of immuno-modulatory 
therapy.  An understanding of the signaling pathways regulating TLR-dependent 
inflammatory responses in ASM is an important area of further investigation.  
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Figure Legends 
Figure 1. Schematic overview of MAPK pathways regulating airway smooth muscle 
functions  A variety of external stimuli activate immune cells or airway epithelial cells to 
release a variety of biological mediators. These mediators transduce their effects through 
ERK, p38 or JNK signaling cascades leading to expression of genes that modulate airway 
smooth muscle contractile, proliferative and secretory responses. 
Figure 2. NF-κB signal transduction pathways. In resting cells, the majority of NF-κB 
is bound to I-κB inhibitory protein, often IκBκ, which masks the nuclear localisation 
sequence (NLS) and holds the complex in the cytoplasm. In the ‘conical’ or ‘classical’ 
NF-κB activation pathway, ligand binding to a cell surface receptor (e.g. tumor necrosis 
factor-receptor (TNFR) or Toll-like receptor) recruits adaptors (e.g., TRAFs and RIP) 
leading to the recruitment of an IKK complex directly onto the cytoplasmic adaptors, 
activating the IKK complex. IKK then phosphorylates IκB at two serine residues, which 
leads to its ubiquitination and degradation by the proteasome. NF-κB then enters the 
nucleus to turn on target genes. TNFR activation can also lead to the phosphorylation of 
p65 at Ser 276 and 536, and recruitment of cofactors such as p/CAF (via PKCβ) to 
heighten transcription. TCR engagement leads to recruitment and activation of receptor-
associated tyrosine kinases of the Src and Syk families. The latter phosphorylate 
phospholipase C and phosphatidylinositol 3-kinase (PI3K). Phosphorylation of 
phosphoinositides by PI3K leads to membrane recruitment and activation of PDK1, 
which may directly phosphorylate and activate PKCθ to control further recruitment of 
CARMA1 into the signaling complex. Assembly of these molecules into lipid rafts and 
PKCθ-dependent phosphorylation of CARMA1 initiate recruitment of BCL10 and 
MALT1 and possibly TRAF6 and TAK1, leading to IKK activation. The general model 
shown here for TCR signaling can also be applied to BCR signaling, although a role of 
PDK1 in this pathway needs to be demonstrated and instead of PKCθ, it involves PKCβ. 
The non-canonical or non-classical pathway differs from the canonical pathway in that 
only certain receptor signals (e.g., Lymphotoxin B (LTb), B-cell activating factor 
(BAFF), CD40) activate this pathway and because it proceeds through an IKK complex 
that contains two IKKα subunits (but not NEMO). In the noncanonical pathway, receptor 
binding leads to activation of the NF-κB-inducing kinase NIK, which phosphorylates and 
activates an IKKα complex, which in turn phosphorylates two serine residues adjacent to 
the ankyrin repeat C-terminal IκB domain of p100, leading to its partial proteolysis and 
liberation of the p52/RelB complex. This complex then enters the nucleus to turn on 
target genes. Figure adapted from Edwards et al., 2008 [66]. 
Figure 3. Schematic overview of the mechanism underlying TNF-α and IFN-γ 
synergism IFN-γ and TNF-α synergistically modulate the expression of different 
inflammatory genes such ICAM-1, RANTES, IL-8 and CD38. Their cooperativity may 
be explained at the receptor level by the IFNγ-induced up-regulation of TNF-α receptors 
or vice-versa. Alternatively, both cytokines may collaborate at the gene level by 
increasing promoter activation through a synergistic interaction between transcription 
factors activated by IFN-γ (STATs, IRF-1) and TNF-α (NF-κB). Another mechanism 
underlying such cooperation could be the induction of defined genes by TNF-α via 
activation of the autocrine action of IFN-β. 
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